Investigating how blood pressure and cholesterol medications may prevent dementia
Official title: The effect of antihypertensive and statin therapy on dementia incidence: a novel analytical approach in large electronic health record datasets with long follow-up times and minimal loss to follow-up
Funded at Stanford University · NIH-10993092 · Data updated 2026-11-12
This study is looking at whether certain blood pressure and cholesterol medications can help prevent Alzheimer's and other types of dementia, using health records from many patients to see how well these treatments work over time.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | December 1, 2023 |
| Project end | November 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $675,874 |
| NIH project number | 5R01AG084535-02 |
| Project ID | NIH-10993092 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals at risk for Alzheimer's disease who are also receiving antihypertensive or statin medications.
✕Less likely to help
Patients who are not at risk for Alzheimer's disease or who are not on antihypertensive or statin therapies may not benefit from this research.
What this research studies
This research explores the potential of antihypertensive and statin therapies to prevent Alzheimer's disease and related dementias by analyzing large electronic health record datasets. The study utilizes a novel analytical approach that examines patients' responses to medication based on specific clinical thresholds, allowing for a more accurate assessment of the medications' effects over long follow-up periods. By leveraging data from multiple health systems, the research aims to provide insights that could lead to better prevention strategies for dementia. Patients' medication adherence and health outcomes will be closely monitored to understand the long-term impacts of these therapies.
Why it matters
Potential benefit: If successful, this research could lead to improved prevention strategies for Alzheimer's disease and related dementias, potentially reducing the incidence of these conditions.
How similar studies have gone: Previous research has shown mixed results regarding the effects of these medications on dementia prevention, making this approach both innovative and necessary to clarify existing uncertainties.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Geldsetzer, Pascal — Stanford University
- Study coordinator: Geldsetzer, Pascal
Related research
Other NIH-funded projects on the same topics.
-
Investigating how DNA damage and repair mechanisms are altered in ALS and frontotemporal dementia.
This study is looking at how problems with DNA repair might contribute to conditions like ALS and frontotemporal dementia, and it’s testing ways to fix these issues in cells from patients to help develop new treatments.
-
Synthetic protein mimetics to treat Lewy Body Dementia
A new therapeutic approach using engineered protein-like molecules to block the harmful protein clumps that cause Lewy Body Dementia.
-
Dementia care staff study: adapting a US survey for use in many countries
A study is adapting and testing a survey for dementia care workers in the US, Brazil, Switzerland, and Ghana to help understand why workers stay in their jobs and how to improve care.
-
Dementia care staff study: adapting a survey for use in many countries
A multinational study will adapt and test a U.S. dementia-care worker survey in Brazil, Switzerland, and Ghana to help understand why staff stay in or leave long-term care settings.
-
Study of Dementia Care Staff in 4 Countries: Adapting Caregiver Surveys Across Cultures
A multinational project will adapt and test a dementia care worker survey so researchers can compare care environments across the US, Brazil, Switzerland, and Ghana.
-
New biomarkers to distinguish LATE from Alzheimer’s disease in dementia
A study to develop blood and CSF tests that can tell apart LATE from Alzheimer’s disease in people with dementia.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.